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Excipients, considered “inactive ingredients,” are a major component of formulated drugs and play
key roles in their pharmacokinetics. Despite their pervasiveness, whether they are active on any targets
has not been systematically explored. We computed the likelihood that approved excipients would bind
to molecular targets. Testing in vitro revealed 25 excipient activities, ranging from low-nanomolar to
high-micromolar concentration. Another 109 activities were identified by testing against clinical safety targets.
In cellular models, five excipients had fingerprints predictive of system-level toxicity. Exposures of seven
excipients were investigated, and in certain populations, two of thesemay reach levels of in vitro target potency,
including brain and gut exposure of thimerosal and its major metabolite, which had dopamine D3 receptor
dissociation constant Kd values of 320 and 210 nM, respectively. Although most excipients deserve their status
as inert, many approved excipients may directly modulate physiologically relevant targets.
F
or most drug products, the major com-
ponents by mass are not the active phar-
maceutical ingredient (API) but rather
are excipients; these are classified as “in-
active ingredients” in the FDA’s Inactive
IngredientsDatabase (IID;www.fda.gov/Drugs/
InformationOnDrugs/ucm113978.htm). Exam-
ples of excipients are molecules such as lactose,
pectin, and xanthan gum, which stabilize the
API in pill form; antioxidants such as propyl
gallate that improve shelf life; detergents such
as sodium lauryl sulfate that solubilize the API
in the gut; and dyes such as FD&C YellowNo. 5
(tartrazine), D&C Red No. 28 (Phloxine B),
and FD&C Blue No. 1 (Brilliant Blue FCF) that
color medicines so that they can be better dis-
tinguished by patients and pharmacists. In
many drug formulations, excipients can reach
concentrations of hundreds of micromolar to
millimolar in the gastrointestinal tract, up to
100 times the concentration achieved by the API.
Despite excipients’widespread use, their ac-
tivity onmolecular targets has not been system-
atically investigated; their “inactive” designation
derives fromgross tolerability studies in animals
or from historical precedents. Most approved
excipients lack obvious toxicity at allowed con-
centrations in animal studies. However, the
ways in which they interact with molecular
targets—and thus how they might perturb
pharmacology in a way not visible in whole-
animal tests—have remained largely unex-
plored. A few, such as bithionol [21 CFR 700.11
(1)] and amaranth, formerly known as FD&C
RedNo. 2 [21CFR81.30 (2)], have been removed
from use over concerns of photosensitization
and tumorigenicity (3), respectively. Some ex-
cipients, such as Methylene Blue, are used di-
rectly as drugs; others closely resemble known
bioactives (Fig. 1A). Thus, although approved
excipients may lack gross physiological effects,
it is conceivable that some may in fact have
specific activity on molecular targets, perturb-
ing their functions and those of the cellular
networks in which they are involved. Mean-
while, approved excipients may be swapped in
drug formulations (4) as long as they do not
affect the pharmacokinetics of the API. This
could affect drug activity, as different excipients
would be expected to have different target
activities, influencing the overall side effects
of the medicine.
Predicting and testing excipient activity
on in vitro targets
We used a two-part strategy to systematically
investigate the activity of approved inactive
ingredients against biologically relevant mo-
lecular targets. First, we computationally pre-
dicted plausible targets for excipients from
among 3000 medically relevant proteins, using
chemoinformatic (5) inference (6, 7), an ap-
proach that has previously been used to pre-
dict off-targets and mechanism-of-action targets
for drugs and probes (8–10). Second, we em-
pirically screened widely used excipients against
a panel of 28 toxicity-related targets regularly
used to identify potential clinical adverse events
of drug candidates (targets associated with
clinical safety) (11), and against several other
targets with important roles in drug toxicity or
drug activity (such as the organic anion trans-
porter; see below).
The chemoinformatic Similarity Ensemble
Approach (SEA; http://sea16.ucsf.bkslab.org)
posits that targets with ligands that resemble a
bait compound—here, an excipient—may also
bind that compound. This approach has been
used to predict side effects and mechanism-
of-action targets for drugs (12–14). Of the 3296
FDA-approved excipients in the IID, 639 ex-
cipients that are well-defined, monomeric
molecules—excluding, for instance, compound
excipients such as honey and dye mixtures
[see http://excipients.ucsf.bkslab.org (15)]—
were computationally screened by SEA against
3117 human targets in the ChEMBL database
for which ligands are known. From the nearly
2 million possible excipient-target pairs im-
plied, just over 20,000 emerged as plausible,
with SEA E-values of 10–5 or better [these E-
values, akin to those in BLAST (16–18), reflect
the likelihood that a prediction would occur at
random; lower E-values are more significant].
Of these, 69 excipient-target pairs were priori-
tized by visual inspection of the excipient ver-
sus the target ligands, eliminating those, for
instance, where there was a key physical dif-
ference between the excipient “bait” and the
ligands of the target (such as a charge group
that might be important for binding) that was
overlooked in the overall chemoinformatic sim-
ilarity, as in previous studies (6, 12, 13). These
69 were tested experimentally in vitro in func-
tional assays, typically with full dose-response
curves (Fig. 1). Nineteen excipients were found
to be active against at least one of 12 targets,
including muscarinic acetylcholine receptors,
the intestinal organic anion transporter 2B1
(OATP2B1), and catechol O-methyltransferase
(COMT), for a total of 25 excipient-target activi-
ties, a 36% success rate (characteristic excipients
are shown in Table 1; tables S1 to S5 list all 69
predictions, including those that failed to confirm
experimentally). Active excipients were counter-
screened for colloidal aggregation (19–21), a com-
mon source of false positives in vitro; any excipient
for which aggregation was observed within an
order of magnitude of its target activity was dis-
counted as potentially artifactual (22). On-target
activities well above predicted fed-gut con-
centrations were also excluded [estimated as
the maximum allowed dosage into a 250-ml
volume (23)].
In a different approach, we experimental-
ly screened 73 commonly used excipients
against a panel of 28 targets associated with
drug clinical safety (11), and also against other
bio-relevant targets including the drug target
VMAT2, the well-known ion channel toxicity
targets Nav1.5 and Cav1.2, and two transport-
ers with roles in drug pharmacokinetics, BSEP
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and OATP2B1. Of these, 32 excipients were
active against one or more targets, for a total
of 109 activities, almost all of which have po-
tency values of 30 mM or less (characteristic
excipients are shown in Table 2; table S6 lists
all excipients tested against the clinical safety
panel). The panel involves both binding and
functional assays; for enzymes and transport-
ers functional inhibition was used, whereas
for receptors such as 5HT2B and the hERG
ion channel, both radioligand binding and
functional assays were typically performed.
Overall, just over 50% of these activities were
measured in functional assays.
From the two approaches, 38 “inactive in-
gredients” emerged with 134 activities against
44 targets (Tables 1 and 2 and tables S1 to S3).
These activities ranged from 15 nM to 260 mM;
30 (22%) were submicromolar, with several in
the low- to mid-nanomolar range, and another
37% were lower than 10 mM. These activities
are more potent than the on-target activities of
some small-molecule therapeutic drugs, which
have a median affinity of ~20 nM (24).
Fig. 1. Motivation for testing excipient activity, operational workflow, and
selected in vitro concentration-response curves. (A) The similarity between
excipients (top) and FDA-approved drugs (bottom). Benzethonium chloride is
itself FDA-approved as a topical antiseptic wash. (B) Workflow. More than
600 molecular excipients were screened computationally, and a list of potential
protein targets was predicted for each one on the basis of its SEA E-value. A
subset of high-ranking excipient-target pairs was tested in vitro. In a second
set of experiments, commonly used excipients were experimentally tested against
a panel of clinical toxicity targets; these tests were unrelated to the SEA
predictions, although sometimes they overlapped. (C) Molecular structures of
thimerosal and ethyl mercury. (D) Concentration-response curves of selected
excipient-target pairs with activity ranging from low-nanomolar (propyl gallate
inhibition of COMT) to mid-micromolar (tartrazine binding to dopamine D1). Red
curves represent a reference positive control; blue curves represent excipient
binding: (a) propyl gallate and reference compound tolcapone binding to COMT;
(b) tartrazine and reference compound (+)-butaclamol binding to DRD1; (c) diethyl
phthalate and reference compound RO 20-1724 binding to PDE4D; (d) thimerosal
and reference compound (+)-butaclamol binding to DRD3; (e) butylparaben and
reference compound L670596 binding to TBXA2R; (f) benzethonium chloride and
reference compound potriptyline binding to SLC6A2 (previously known). The D3
binding curve for thimerosal is one representative of replicates in three separate
laboratories. Additional dose-response curves are provided in fig. S1.
Excipient cell-based toxicities
Although these activities belie the designation
of these ingredients as “inactive,” they do not
necessarily imply that the excipients will have
activities on organ systems that would mani-
fest in health or behavioral changes of an in-
dividual. Such systemic disturbances depend
on integrated effects on tissues, and on expo-
sure of the excipient to their targets in relevant
contexts in the body.
Accordingly, 12 of the target-active excipi-
ents were further investigated with the BioMAP
Diversity PLUS panel, a suite of cell-based sys-
tems widely used tomodel drug- and chemical-
induced effects and toxicology in vascular,
lung, skin, and inflammatory tissues, among
others (25–27) (see supplementary materials).
These 12 were prioritized for testing by several
criteria, including their frequency of use in
drug formulations and their coverage of differ-
ent excipient functions (e.g., colorants, antimicro-
bials, antioxidants, emulsifiers, and surfactants).
Although wemostly tested excipients found to
be active in the in vitro assays, several inactive
ones were also included. Excipients with poor
solubility were excluded. Each excipient gen-
erated a profile on 148 biomarker readouts in
the cells, at four different concentrations (22)
(Table 3 and fig. S14).
These effects were compared to more than
4000 drug and chemical reference profiles in the
BioMAP database. For example, butylparaben,
a widely used excipient coformulatedwith APIs
as varied as acetaminophen, hydrocodone, di-
phenhydramine, and fluoxetine, had a cellular
efficacy fingerprint suggesting inflammation-
related activity. This excipient dose-dependently
decreasedMCP-1 (monocyte chemoattractant
protein 1, or CCL2) and sPGE2 (soluble prosta-
glandin E2) in peripheral blood mononuclear
cells and venular endothelial cells, whereas its
biomarker profile shared six common activ-
ities with the anti-inflammatory nabumetone
at 30 mM(Pearson correlation r=0.735) (fig. S2).
Meanwhile, propyl gallate, an excipient cofor-
mulated in drugs such as Advil Sinus Con-
gestion and Pain, Janumet, ezetimibe, and
simvastatin, was antiproliferative in B and
T cells, coronary artery smoothmuscle cells, en-
dothelial cells, and fibroblasts, at 10 or 30 mM.
Propyl gallatehadcellular activities thatmapped
to the immunomodulatory and inflammation-
related activities of phenazopyridine (fig. S7)
and mycophenolate, anesthetic, and immu-
nosuppressant drugs, respectively. Intriguing-
ly, at lower concentrations, propyl gallate’s
profile most resembled that of caffeic acid
phenethyl ester, a 15-lipoxygenase inhibitor
with anti-inflammatory and immunomodu-
latory properties, consistent with our obser-
vation that propyl gallate is an inhibitor of
5-lipoxygenase with a potency of 430 nM
(Table 2). Another interesting example is di-
ethyl phthalate. Notably, diethyl phthalate
modulated tumor necrosis factor–a (TNF-a)
in a dose-dependent manner (Table 3), as pre-
viously observed (28). Furthermore, TNF-a
production can be affected by PDE4 inhibition
(29)—an in vitro activity of diethyl phthalate
determined in this study (concentration of
50% inhibition IC50 = 8.5 mM; Table 1). Fi-
nally, the BioMap profile of diethyl phthalate
matched that of roflumilast (r = 0.72) (fig.
S11), a PDE4 inhibitor used to treat chronic
obstructive pulmonary disease (COPD). Sev-
eral of the excipients that were active in iso-
lated enzyme and receptor assays, including
aspartame, propylene glycol, and tartrazine
Fig. 2. Time-concentration profiles of excipients administered to rats. (A to D) Time-concentration curves of blood exposure in rats after i.v. (1 mg/kg)
application of excipients and oral administration of propyl gallate (10 mg/kg) (A), D&C Red No. 6 (1 mg/kg) (B), cetylpyridinium chloride (1 mg/kg) (C), and FD&C
Red No. 3 (1 mg/kg) (D). Insets are expanded views of the oral administration curves. Error bars denote SD from measurements in three rats.
Table 1. Excipient–off-target predictions with SEA, confirmed by in vitro binding assays. Examples of marketed drugs containing the excipient, and
maximal excipient dosages allowed by the FDA in any single formulation, are also shown. Functions are drawn from the Handbook of Pharmaceutical Excipients
(64) except as noted. All drugs listed are administered orally.
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ..
*From (65). †SEA predicted PDE4B and PDE1, neither of which were readily available for testing, but the isozyme PDE4D was.
find causal correlation between pre- and post-
natal vaccination and neuropsychologicalman-
ifestations (34–36). Still, because thimerosal is
amercury derivative (Fig. 1C), there has been a
move to limit or eliminate it in parenteral for-
mulations, particularly in pediatric vaccines
(37, 38). Indeed, thimerosal was removed from
childhood vaccines in the United States in 2001
(33). Nonetheless, the molecule is still used
in industrial preparation of vaccines, and it
continues to occur in multidose adult influ-
enza vaccines in the United States (39, 40) and
in multidose vaccines, including for infant vac-




multidose formulations, a patient could receive 12.5
to 25 mg of thimerosal per vaccination (38–40).
We find that thimerosal binds to the dopa-
mine D3 receptor with a Kd of 320 nM, where-
as its primarymetabolite, ethylmercury, binds
to the same receptor with a Kd of ~210 nM
and to the dopamine D5 receptor with a Kd of
~150 nM (Table 2 and table S7). Mercury levels
after newborn and infant vaccination con-
taining thimerosal reached an average Cmax
of 5 ng/ml (25 nM) in the blood, with a calcu-
lated half-life t1/2 of 3.7 days and a complete
clearance 30 days after vaccination (41). The
level of Hg in the stool was higher, reaching an
average Cmax of 45 ng/ml (225 nM) (41). Al-
lometric scaling from infant monkeys (42), the
only studymeasuring brain exposure, projected
an estimated 13 to 24 ng/g (65 to 120 nM) Cmax
of mercury in the brain of human infants, with
t1/2 of ~21 days (fig. S15A and table S8). Mean-
while, in a study measuring results after re-
peated vaccination in human adults (43), the
median blood concentration was 0.33 ng/ml
(0.17 to 1.3 ng/ml = 0.85 to 6.5 nM) for Hg and
0.14 ng/ml (0.06 to 0.43 ng/ml = 0.7 to 2.2 nM)
for ethyl mercury, respectively, with a mean
half-life of 5.6 days. Although the blood con-
centration of Hg in adults was substantially
lower than projected for infants, the mercury-
containing molecules are expected to concen-
trate and accumulate in the brain, reaching
concentrations of 25 to 30 nM.
Taken together, these observations suggest
that thimerosal and ethyl mercury may reach
gut and brain concentrations in the human
infant that overlap with their affinity (Kd) val-
ues for the dopamine D3 receptor (Table 2).
For this receptor, the safety margin for the
ratio of pharmacokinetic exposure to IC75 is
~1 (i.e., the exposed concentration should be
less than concentration required for 75% re-
ceptor occupancy) (44). This does not demon-
strate in vivo D3 receptor activity of thimerosal
and ethyl mercury, even for infants (who are
no longer exposed to this excipient in the devel-
oped world). Still, the activity on the dopamine
D3 receptor, and for ethyl mercury the dopa-
mineD5 receptor—both important targets and
antitargets, present both in brain and gut—
does make a physiological effect by thimero-
sal plausible.
Discussion
A key observation from this study is thatmany
“inactive ingredients,” ubiquitous in drug for-
mulations, have direct activities against biolog-
ically relevant enzymes, receptors, ion channels,
and transporters in vitro. Overall, we observed
134 activities for 38 excipients were observed
(Tables 1 and 2 and tables S1 to S3). These ac-
tivities covered a wide range: 15 nM for propyl
gallate on COMT; mid-nanomolar activities
for thimerosal at the dopamine D3 receptor,
of FD&C Red No. 3 at phosphodiesterase 3A
(PDE3A), and for benzethonium chloride at
the vesicular monoamine transporter VMAT2;
low-micromolar activities for cetylpyridinium
chloride and benzethonium chloride at the
hERG ion channel; and mid-micromolar activ-
ities for butylparaben at the muscarinic receptor
CHRM1 and for diethyl phthalate at PDE4D.
Many of these enzymes and receptors have
crucial roles in neurotransmitter signaling, in-
cluding COMT, the phosphodiesterases, the
VMAT2 transporter, and the dopamine and
muscarinic receptors, which have pleiotropic
physiological effects and are targeted by mul-
tiple therapeutic drugs, whereas the hERG ion
channel is notorious for serious adverse drug-
related cardiac effects. The median, in vitro
activity of all tested excipients that hadmeasur-
able activity was 5.9 mM. For several excipients,
such as propyl gallate, thimerosal, and FD&C
Red No. 3, their target-based IC50 values over-
lap with those of therapeutic drugs (24). At the
same time, many of these excipients are ad-
ministered at much higher doses than the API
whose physical behavior and stability they are
intended to modulate and protect. Although
most will never reach systemic circulation, it is
clear, even from this preliminary study, that
excipients such as cetylpyridinium chloride
and thimerosal do so at concentrations that are
high enough to plausibly affect the function of
the proteins identified here, all of which are
well-accepted therapeutic or toxicity targets.
Although the systemic exposure of most ex-
cipients remains limited at regulated maxi-
mum doses inmedicines, the wide and chronic
use of multiple drugs, sometimes with over-
lapping excipients [for instance, in elderly pop-
ulations (45)] could result in higher dosing of
excipients than allowed for in any one drug,
and thus in increased systemic levels. The
widespread occurrence in foods, drinks, and
cosmetics of many of the same excipients that
occur in drugs may further exacerbate excip-
ient exposure. Indeed, many of the excipients
investigated here—including colorants such as
tartrazine, FD&C Red No. 40, and FD&C Blue
No. 1; preservatives such propyl gallate; and
(FD&C Yellow No. 5), had no measurable ac-
tivity in these cell-based systems.
Systemic exposure of excipients
in animal models
Excipients are often exposed at high concen-
trations to targets in the gut epithelia, includ-
ing the intestinal uptake transporter OATP2B1, 
calcium and sodium ion channels, and bile acid 
transporters; however, for systemic impact they 
must cross intestinal and metabolic barriers 
and enter the general circulation. Accordingly, 
we investigated seven of the more active and 
widely used excipients for exposure in blood 
after oral dosing in a rodent model (Table 4 
and Fig. 2). Most  did not  reach blood concen-
trations high enough to modulate their targets 
upon oral dosing, which suggests that despite 
potent target-based and even cell-based activ-
ities, they were sequestered in the gut or were 
rapidly metabolized. Examples include butyl-
paraben, which—although administered at 
doses up to 8 mg (5 ml) in several medications, 
implying a concentration of 160 mM, in the fed-
state gut—reaches only negligible concentra-
tions in the blood when dosed at 10 mg/kg in 
the rat, likely reflecting rapid metabolism in 
the blood. Similarly, FD&C Red No. 3  reaches  
a peak concentration (Cmax) value of 17 nM 
only after a 1.0 mg/kg oral dose, making its 
92 nM inhibition of phosphodiesterase 3A 
(PDE3A) less concerning, particularly with a 
99% plasma protein binding. The 15 nM COMT 
inhibitor propyl gallate reaches Cmax values of 
5 nM only after a 10 mg/kg oral dose, much  
higher than its maximum dose of 2 mg in drug 
formulations, even allowing for allometric scal-
ing. [However, as discussed below, propyl gal-
late is used in much higher amounts in food, 
and there is some indication that COMT has 
a role in gut disorders, where propylparaben 
will reach much higher concentrations (30).] 
Moreover, at least therapeutically, most of 
COMT’s functions are in the central nervous 
system, and it is likely that brain exposure 
would be even lower than in the general 
circulation. Of the orally dosed excipients, 
only the antiseptic cetylpyridinium chloride, 
which occurs in mouthwash, reached a blood 
Cmax that was in the range of its activity against 
the dopamine D3 receptor (Cmax = 260  nM,  
IC50 = 550  nM).
There are other routes to the systemic circu-
lation, such as excipients in injected drug for-
mulations. One we investigated was thimerosal 
(www.spectrumchemical.com/MSDS/TH125_ 
AGHS.pdf), an antibacterial present in several 
parenteral applications, notably vaccines such 
as those for influenza and diphtheria/tetanus, 
but also broadly used in ophthalmic solutions (31), 
antivenom injections (32), and topical applications 
of dermatological products (33). Thimerosal is 
well known for its discounted association with 
autism, after epidemiological studies failed to
Table 2. Excipient-target activities determined in vitro. The targets are drawn from safety profiling assays generally used for determining off-target effects of drug
candidates and marketed drugs. Functions are drawn from the Handbook of Pharmaceutical Excipients (64) except as noted. Examples of marketed drugs containing the
excipient, and maximal excipient dosages occurring in any single formulation, are shown. Biochemical and radioligand binding data (IC50) are unformatted; functional
data (antagonism/inhibition, IC50; agonism, half maximal effective concentration EC50) are in bold in the Target column. Activity values are accurate to ±20%.
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. .
*From (65). †Oral. ‡Auricular. §Intravenous. ¶Topical. #Inhalation. **An agonist effect was observed.
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Table 3. Excipient activity in cell-based model systems. BioMAP Diversity PLUS profiles for 12 excipients are shown. Each section of the spectrum
corresponds to a different cell or tissue system (22). Profiles represent concentration responses across the assays: green, 1.1 mM; yellow, 3.3 mM; orange, 10 mM; red,
30 mM. Upward and downward strokes represent increased and decreased levels, respectively, in log scale (see tartrazine for reference). The gray shaded area
represents the baseline response range. The rightmost columns show toxicity signatures and the closest drug matches from the BioMAP database with corresponding
correlation between the two profiles. Cytotoxicity is indicated by thin black arrows; antiproliferative effects are marked by gray arrows. Cell types corresponding
to assay codes: 3C, venular endothelial cells (VECs); 4H, VECs; LPS, peripheral blood mononuclear cells (PBMCs), endothelial cells (ECs); SAg, PBMCs,
ECs; BT, PBMCs, B cells; BF4T, bronchial epithelial cells (BECs), dermal fibroblasts; BE3C, BECs; CASM3C, coronary artery smooth muscle cells; HDF3CGF,
fibroblasts; KF3CT, keratinocytes, fibroblasts; MyoF, lung fibroblasts; iMphg, macrophages, VECs. See supplementary materials for detailed explanation.
For measurements on all tested excipients, see figs. S2 to S13.
beyond the scope of this study, such excipient
switching is well known. It is allowed as long
as switching these “inactive ingredients” can
be shown not to compromise the exposure of
the API itself, and as long as replacements are
in fact as inactive as they are assumed to be
(4). If, however, the excipients have their own
on-target activity, and if they are exposed to
that target, the last assumption breaks down.
There may be early indications that this is the
case for some drug formulations.
An example is the API levothyroxine (T4),
available in Synthroid and in generic formu-
lations, which contains Aluminum Lake dyes
and lactose, among other excipients (www.
rxabbvie.com/pdf/synthroid.pdf). There has
been concern that dye and food allergies, as
well as gastrointestinal comorbidities, may
arise from these excipients (54, 55). Levo-
thyroxine can also be delivered without these
excipients in a soft gel form, containing only
water, glycerin, and gelatin (56). The removal
of the other excipients appears to aid the ab-
sorption of levothyroxine with less dependence
on the level of stomach acid and fewer inter-
actions with other medications (57, 58).
A second example is the API ketamine, for-
mulatedwith the antimicrobial benzethonium
chloride as the sole excipient in an intra-
venous formulation. Benzethonium chlo-
ride has well-documented toxicity (59), and
we find it to have multiple in vitro activities
(Table 2). Ketalar has had substantial reports of
ventricular arrhythmias (www.accessdata.fda.
gov/drugsatfda_docs/label/2012/016812s039lbl.
pdf; https://open.fda.gov/data/faers/). Such car-
diac adverse drug reactions often reflect activity
on thehERG ion channel (60).Whereas ketamine
itself hasnodetectablehERGactivity,we find that
benzethoniumchloride is a 0.5 mMhERGblocker.
Although benzethonium chloride should only
reach a concentration of 90 nM in the blood
given its dosage with ketamine, this is within
the factor of 30 safety window at which one
may be concerned about adverse events. We
caution that these are just examples of possible
adverse effects and are inevitably muddied by
several confounds, including those inherent
in databases such as the FDA Adverse Event
Reporting System (FAERS) (61). Disentangling
the possible activities of these and other exci-
pients from the drugswithwhich they are paired
will demand further investigation; no definite
conclusions should be drawn from this study.
This work retains several caveats. Perhaps
the most important is the lack of systemic
exposure formany excipients tested here, even
those that have potent in vitro activities. The
physical properties of these molecules often
preclude gut absorption, or they are rapidly
metabolized. Thus, despite potent in vitro ac-
tivities (Tables 1 and 2), and even activities in
cellular assays designed to model organ-level
toxicities (Table 3), these excipients effectively
remain inert in the body. Also, we emphasize
that most excipients examined were inactive
even in vitro, at least against the targets priori-
tized here; a majority of the excipients tested
showed no binding, no functional activity, and
no toxicity in the assays conducted. Finally,
even when we observed on-target binding and
cellular toxicity, these were not directly linked
to whole-animal toxicity. What this study does
is reveal excipient activity on biological targets
associated with therapeutic and toxic side ef-
fects; it does not demonstrate that even the
target active excipients lead to toxic effects.
Still, knowing these target-based activities al-
lows investigation of particular excipients for
particular effects in a way rarely possible with
whole-animal studies alone.
These cautions should not obscure the prin-
cipal observations from this work: Drug excip-
ients, classified as “inactive ingredients” and
often present in large amounts in single-drug
formulations, can have substantial activities
Table 4. Pharmacokinetics parameters of excipients. Shown are pharmacokinetic parameters in rats of excipients after i.v. (1 mg/kg) and oral
administration (cetylpyridinium chloride, 1 mg/kg; butylparaben, 10 mg/kg; FD&C Red No. 3, 1 mg/kg; D&C Red No. 6, 1 mg/kg; propyl gallate, 10 mg/kg).
Diethyl phthalate and thimerosal pharmacokinetic data were obtained from the literature, as noted. MDCK-LE Papp is the apparent permeability measured in
the Madin-Darby canine kidney permeability assay. AUC, area under curve; %F, bioavailability; N.D., not determined; d.n., dose normalized.











Oral Cmax (nM) %F
Butylparaben TBXA2R 19 8.3 N.D.* N.D.* N.D.* <2.6 N.D.*
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .
Cetylpyridinium chloride DRD3 0.55 <0.5 9.7 15,972 4,052 260 5.4
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .
FD&C Red No. 3 PDE3A 0.092 <0.5 3.4 4,826 32 16.9 0.7
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .
D&C Red No. 6 SLCO1B1 3.1 <1.2 6.9 30,511 776 164 2.5
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .
Diethyl phthalate PDE4D2 16 — 1.0† 553† 350† 253† N.D.†
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .
Propyl gallate COMT 0.015 11.7 4.9 6908 N.D.* <8.9 N.D.*
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .
Thimerosal DRD3 0.32 — 24.2‡ N.D. N.D.
30 to 40 ng/g‡
(70 to 105 nM)
N.D.
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .
*Only a single time point had values above the LOQ, so a t1/2 and an AUC cannot be calculated. †From (66). ‡From (42). In the case of thimerosal, Hg concentration was measured in the
primate brain (ng/g) after intramuscular injection.
sweeteners such as aspartame—occur in food 
and drinks in even higher amounts  than they  
do in drugs (for instance, propyl gallate is al-
lowed in foods at an acceptable daily intake of 
0.5 mg kg–1 day–1, a 35-mg daily intake for a 
70-kg adult, which might bring the COMT ef-
fect within the range of that absorbed in the rat 
study). Altered gut absorption (46) and local ef-
fects on the microbiome (47) could exacerbate 
unexpected effects of target-active excipients.
Although most excipients may not reach 
relevant systemic exposure, two of the seven 
for which pharmacokinetics were explored—
cetylpyridinium chloride and thimerosal—may 
do so. No study has demonstrated that thi-
merosal leads to in vivo toxicities, and we have 
not done so here. Still, our observation that 
the affinities of thimerosal and ethyl mercury 
for the D3 dopamine receptor overlap their 
pharmacokinetic exposure makes the occur-
rence of target-based activity at least plausible. 
Consistent with this view, rats treated with thi-
merosal postnatally had impaired locomotor 
function, increased anxiety/neophobia in the 
open field, and alterations in social behavior 
(48), all side effects that are well-precedented 
for dopamine receptor ligands (49, 50). In these 
rodent studies, immunohistochemistry revealed 
a decline in striatal D2 receptor density (48), and 
prenatal treatment with thimerosal impaired 
the serotonergic and dopaminergic systems in 
the rat brain (51). We note that two independent 
studies in nonhuman primates did not find al-
terations in behavior after thimerosal treatment 
(52); however, immunohistochemistry experi-
ments were not pursued in either study, and in 
one study the behavioral tests lacked chal-
lenges to dopaminergic components (53).
For excipients with inherent on-target activ-
ity, it is plausible that they will lead to differ-
ent outcomes than the API alone would have, 
as could different excipients used with the 
same API. Although a detailed investigation is
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on medically relevant targets. Excipient expo-
sure may be especially high in populations, 
such  as the elderly, that take multiple medi-
cines together. With affinities that dip to the 
low- and mid-nanomolar, the in vitro activities 
of excipients overlap with those of therapeutic 
drugs (24). Although many excipients do not 
reach the general circulation, several do, as 
shown even in this limited, proof-of-concept 
study. Once they do so, they can have unplanned 
pharmacology of their own. Most excipients 
genuinely are inactive and will continue to play 
crucial roles in drug formulations; by contrast, 
those excipients that have relevant in vitro ac-
tivities and that reach substantial systemic con-
centrations may merit further review, beyond 
the gross animal physiology previously under-
taken in safety studies.
This work suggests a systematic method to 
identify such active “inactive ingredients,” in-
cluding the detection of allergenic and immu-
nogenic properties. Replacements are readily 
available for most excipients, including non-
catechol antioxidants for propyl gallate, plant-
based colorants for the aromatic azo dyes, 
and, in the case of thimerosal, simply replacing  
multidose formulations with single-dose vials 
(which do not, even now, have thimerosal in 
them), with relatively minor cost effect (62). 
However, many of the excipients studied here, 
such as propyl gallate, diethyl phthalate, butyl-
paraben, and tartrazine (63), also occur as food 
and cosmetic additives, often in far larger 
amounts than in drugs; this too merits review.
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